London – The UK’s Medical Research Council (MRC) and Technology Strategy Board will jointly invest more than EUR3.5m to fund seven research projects focused on personalised medicine. Four projects will focus on the development of biomarkers to predict response to inflammation and immunology therapies. Three of the projects will be led by GlaxoSmithKline, while the remaining four will be split among AstraZeneca, Ig Innovations Ltd, Johnson & Johnson and Randox Laboratories Ltd. The projects are part of the Stratified Medicines Innovation Platform, which was launched last year to provide over EUR45m for personalised medicines research. The Technology Strategy Board, a business-led public body established by the government, also will commit more than EUR180m over the next four years to fund the creation of a network of technology and innovation.